Century Therapeutics Stock Forecast, Price & News

Century Therapeutics (NASDAQ:IPSC) Frequently Asked Questions

Is Century Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Century Therapeutics stock.
View analyst ratings for Century Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Century Therapeutics?

Wall Street analysts have given Century Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Century Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Century Therapeutics' next earnings date?

Century Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Century Therapeutics.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $1.53.
View Century Therapeutics' earnings history.

What price target have analysts set for IPSC?

4 brokerages have issued 1 year target prices for Century Therapeutics' stock. Their forecasts range from $33.00 to $40.00. On average, they anticipate Century Therapeutics' stock price to reach $36.25 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for Century Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Century Therapeutics' key executives?

Century Therapeutics' management team includes the following people:

• Dr. Osvaldo Flores, Pres, CEO & Director (Age 58, Pay $648.9k)
• Dr. Michael C. Diem, Chief Bus. Officer (Age 50, Pay $298.54k)
• Dr. Hyam I. Levitsky, Pres of R&D (Age 63, Pay $502.12k)
• Mr. Douglas Carr CPA, VP of Fin. & Operations
• Dr. Adrienne Farid Ph.D., Chief Operations Officer (Age 59)
• Dr. Gregory Russotti Ph.D., Chief Technology Officer (Age 54)
• Dr. Luis Borges, Chief Scientific Officer (Age 59)
• Mr. Kenneth J. Dow J.D., VP of Law
• Dr. Shane Williams Ph.D., Chief People Officer
• Mr. Mark Wallet, Head of Immunology & VP

Who are some of Century Therapeutics' key competitors?

Some companies that are related to Century Therapeutics include Sana Biotechnology (SANA), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Adagio Therapeutics (ADGI), Recursion Pharmaceuticals (RXRX), SpringWorks Therapeutics (SWTX), Ginkgo Bioworks (DNA), Bavarian Nordic A/S (BVNRY), Soaring Eagle Acquisition (SRNG), Kymera Therapeutics (KYMR), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Instil Bio (TIL) and Vericel (VCEL).
View all of IPSC's competitors.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

When does the company's lock-up period expire?

Century Therapeutics' lock-up period expires on Wednesday, December 15th. Century Therapeutics had issued 10,550,000 shares in its IPO on June 18th. The total size of the offering was $211,000,000 based on an initial share price of $20.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Strs Ohio (0.00%). Company insiders that own Century Therapeutics stock include Eli Casdin and Versant Venture Capital Vi, L.
View institutional ownership trends for Century Therapeutics.

Which institutional investors are buying Century Therapeutics stock?

IPSC stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Century Therapeutics stock in the last two years include Eli Casdin, and Versant Venture Capital Vi, L.
View insider buying and selling activity for Century Therapeutics or or view top insider-buying stocks.

How do I buy shares of Century Therapeutics?

Shares of IPSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $21.50.

How much money does Century Therapeutics make?

Century Therapeutics has a market capitalization of $1.17 billion.

How many employees does Century Therapeutics have?

Century Therapeutics employs 102 workers across the globe.

What is Century Therapeutics' official website?

The official website for Century Therapeutics is www.centurytx.com.

How can I contact Century Therapeutics?

The company can be reached via phone at 267-817-5790 or via email at [email protected].